Mumbai-based customised haircare startup Traya is in talks to raise around ₹300 crore from Belgium-based investment firm Verlinvest, in a deal that would underscore continued investor interest in consumer health and beauty brands with strong digital distribution and repeat purchase potential. The proposed round, equivalent to about $31 million, is still under discussion and the final size, structure and valuation could change before any agreement is signed.
Traya has built its business around a personalised approach to hair loss treatment, combining consultations, diagnostics and product recommendations rather than selling a one-size-fits-all shampoo or serum. That positioning has helped the company stand out in a crowded direct-to-consumer market where many brands compete on branding alone. For investors, the appeal lies in a category with recurring demand, relatively high customer lifetime value and the possibility of moving beyond pure e-commerce into a broader consumer health platform.
Growth Capital Push
If completed, the funding would likely be used to accelerate Traya's expansion across marketing, product development and customer acquisition, while also strengthening its operational backbone. Startups in the personal care and wellness segment have increasingly turned to large growth rounds to support offline experimentation, clinical credibility and deeper retention strategies. For a company like Traya, which sits at the intersection of beauty, wellness and health, capital can be deployed not just for brand building but also for improving the evidence base behind its offerings.
The timing of the talks is notable. India's startup funding environment has remained selective, with investors favouring businesses that can demonstrate efficient growth, strong unit economics and clear paths to profitability. Consumer brands that rely heavily on paid acquisition have faced pressure to prove that they can retain customers beyond the first purchase. A sizeable round from a global consumer investor such as Verlinvest would suggest confidence in Traya's ability to convert early traction into a durable business.
Verlinvest has a history of backing consumer-facing companies across food, beverage, health and lifestyle categories, often taking a long-term view on brand-led businesses. Its interest in Traya would fit that pattern, particularly as Indian consumers increasingly spend on preventive health, personalised wellness and premium self-care products. The haircare market, once dominated by mass-market formulations, has seen a wave of startups promising tailored regimens and medically informed solutions.
Haircare Market Heats Up
Traya's pitch is built on a problem that affects a large and growing consumer base: hair fall and related scalp concerns. In India, where stress, nutrition, pollution and lifestyle factors are often cited as contributors, the category has expanded beyond cosmetics into quasi-clinical care. That shift has created room for startups to charge premium prices, provided they can establish trust and show measurable outcomes.
The company's model also reflects a broader trend in Indian consumer startups toward personalised commerce. Instead of selling a single product, brands are increasingly offering assessments, prescriptions and bundled routines. This approach can improve margins and retention, but it also raises the bar on customer experience, fulfilment and support. Scaling such a model requires not only marketing spend but also disciplined execution across technology, logistics and advisory services.
For Verlinvest, the potential investment would add to a portfolio strategy that has often focused on consumer behaviour shifts rather than short-term hype. For Traya, the deal could provide both capital and institutional validation at a time when category leadership is still up for grabs. The startup would also gain a partner with experience in helping consumer brands expand across markets and channels.
What The Deal Signals
The talks come as Indian venture capital continues to recalibrate after the funding boom of earlier years. Investors are now more selective, but they remain willing to back companies that combine strong brand recall with repeatable demand and credible differentiation. Traya appears to fit that profile better than many discretionary consumer startups because it addresses a persistent problem and operates in a category where outcomes matter.
Still, the transaction is not yet closed, and such discussions can shift on valuation, governance and growth expectations. Any final agreement will likely be watched closely by the startup ecosystem as a signal of how global investors are pricing consumer health brands in India. A successful raise at the reported scale would also reinforce the view that specialised, science-backed consumer businesses can still attract meaningful capital even in a tighter market.
For now, the talks place Traya among a small but growing set of Indian startups that are trying to turn personalised wellness into a scalable, investment-grade business. If the round goes through, it would give the company fresh firepower to compete in one of the country's most dynamic and increasingly sophisticated consumer categories.